News in brief - September 2013

Other new launches, licence changes and updates relevant to general practice.

Lecicarbon A suppositories (sodium hydrogen carbonate/sodium dihydrogen phosphate) release carbon dioxide in the gut, activating intestinal movement and triggering bowel evacuation
Lecicarbon A suppositories (sodium hydrogen carbonate/sodium dihydrogen phosphate) release carbon dioxide in the gut, activating intestinal movement and triggering bowel evacuation
  • Aspire has launched Lecicarbon A suppositories (sodium hydrogen carbonate/sodium dihydrogen phosphate) for the treatment of constipation and for bowel clearance prior to surgical or diagnostic procedures.
  • An immediate-release capsule containing oxycodone (Lynlor) that is licensed for use in children aged 12-18 years has been launched.
  • The pneumococcal vaccine Prevenar 13 can now be given to adults from the age of 18 years for immunisation against invasive disease caused by Streptococcus pneumoniae
  • The combination glaucoma treatment Ganfort (brinzolamide/timolol) is now available in a preservative-free single-use eye drop formulation.
  • A 60mg sustained-release gliclazide tablet (Laaglyda MR) has been launched for the treatment of type II diabetes.
  • Lucentis (ranibizumab) has been approved to treat visual impairment caused by choroidal neovascularisation secondary to pathological myopia.
  • The protein kinase inhibitor Glivec (imatinib) can now be used for children over 1 year of age with acute lymphocytic leukaemia (ALL).
  • The MHRA has warned of an increased risk of cystoid macular oedema in patients treated with docetaxel. Patients who develop impaired vision should have their eyes examined and discontinue treatment with the cytotoxic if the condition in confirmed.
  • In a change to the marketing authorisation, treatment with Tysabri (natalizumab) is now additionally indicated in patients with relapsing-remitting multiple sclerosis with high disease activity despite treatment with glatiramer.
  • Veletri (epoprostenol) is a new formulation of the prostaglandin analogue that is stable at room temperature for at least 24 hours at all concentrations. 

Follow MIMS on Twitter


Read these next

New advice from the SMC

New advice from the SMC

The Scottish Medicines Consortium has issued its latest...

Ranibizumab gains NICE approval for secondary macular oedema

Ranibizumab gains NICE approval for secondary macular oedema

Ranibizumab (Lucentis) can now be prescribed in the...

Monopost: first preservative-free latanoprost eye drops

Monopost: first preservative-free latanoprost eye drops

Spectrum-Thea Pharmaceuticals has launched Monopost,...

Prevenar 13 licensed from 5 years

Prevenar 13 licensed from 5 years

The conjugate pneumococcal vaccine Prevenar 13 is now...

NICE amends ranibizumab guidance

NICE amends ranibizumab guidance

NICE has overturned its original decision to reject...

Prevenar 13 now indicated in adults

Prevenar 13 now indicated in adults

The licence for the pneumococcal conjugate vaccine...


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.